Rhythm Pharmaceuticals (RYTM) Total Current Liabilities (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Total Current Liabilities of $103.2 million for Q1 2026, down 7.71% year-over-year from $111.8 million in Q1 2025, and down 2.59% quarter-over-quarter from $105.9 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Total Current Liabilities (2016 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Total Current Liabilities for 11 consecutive years, with $103.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 7.71% year-over-year to $103.2 million; the TTM figure through Mar 2026 stood at $103.2 million (down 7.71% YoY), while the FY2025 annual figure was $105.9 million, down 8.29% from the prior year.
- Total Current Liabilities eased to $103.2 million in Q1 2026 per RYTM's latest filing, from $105.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $129.5 million in Q2 2025 and bottomed at $33.1 million in Q3 2022.
- Historically, Total Current Liabilities has averaged $72.9 million across 5 years, with a median of $54.7 million in 2024.
- On a YoY basis, Total Current Liabilities climbed as much as 180.56% in 2022 and fell as far as 8.33% in 2022.
- Rhythm Pharmaceuticals' Total Current Liabilities stood at $39.8 million in 2022, then surged by 38.67% to $55.2 million in 2023, then surged by 109.26% to $115.5 million in 2024, then retreated by 8.29% to $105.9 million in 2025, then dropped by 2.59% to $103.2 million in 2026.
- Business Quant data shows RYTM's Total Current Liabilities at $103.2 million in Q1 2026, $105.9 million in Q4 2025, and $104.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | 123.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 123.59 Mn |
| Mar 31, 2026 | 103.20 Mn |
| Dec 31, 2025 | 105.94 Mn |
| Sep 30, 2025 | 104.27 Mn |
| Jun 30, 2025 | 129.46 Mn |
| Mar 31, 2025 | 111.82 Mn |
| Dec 31, 2024 | 115.52 Mn |
| Sep 30, 2024 | 97.61 Mn |
| Jun 30, 2024 | 54.72 Mn |
| Mar 31, 2024 | 54.16 Mn |
| Dec 31, 2023 | 55.20 Mn |
| Sep 30, 2023 | 50.14 Mn |
| Jun 30, 2023 | 46.10 Mn |
| Mar 31, 2023 | 46.03 Mn |
| Dec 31, 2022 | 39.81 Mn |
| Sep 30, 2022 | 33.10 Mn |
| Jun 30, 2022 | 44.57 Mn |
| Mar 31, 2022 | 47.27 Mn |
| Dec 31, 2021 | 43.43 Mn |
| Sep 30, 2021 | 23.47 Mn |